| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Kezar Life Sciences, Inc. [ KZR ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 07/24/2023 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
|||||||||||||||||||||||||
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Employee Stock Option (right to buy) | $22.85 | 07/24/2023 | D | 175,000 | (1) | 01/05/2029 | Common Stock | 175,000 | (2) | 0 | D | ||||
| Employee Stock Option (right to buy) | $2.28 | 07/24/2023 | A | 175,000 | (1) | 01/05/2029 | Common Stock | 175,000 | (2) | 175,000 | D | ||||
| Employee Stock Option (right to buy) | $3.29 | 07/24/2023 | D | 200,000 | (3) | 01/11/2030 | Common Stock | 200,000 | (2) | 0 | D | ||||
| Employee Stock Option (right to buy) | $2.28 | 07/24/2023 | A | 200,000 | (3) | 01/11/2030 | Common Stock | 200,000 | (2) | 200,000 | D | ||||
| Employee Stock Option (right to buy) | $5.45 | 07/24/2023 | D | 1,200,000 | (4) | 01/07/2031 | Common Stock | 1,200,000 | (2) | 0 | D | ||||
| Employee Stock Option (right to buy) | $2.28 | 07/24/2023 | A | 1,200,000 | (4) | 01/07/2031 | Common Stock | 1,200,000 | (2) | 1,200,000 | D | ||||
| Employee Stock Option (right to buy) | $14.55 | 07/24/2023 | D | 500,000 | (5) | 01/04/2032 | Common Stock | 500,000 | (2) | 0 | D | ||||
| Employee Stock Option (right to buy) | $2.28 | 07/24/2023 | A | 500,000 | (5) | 01/04/2032 | Common Stock | 500,000 | (2) | 500,000 | D | ||||
| Employee Stock Option (right to buy) | $6.84 | 07/24/2023 | D | 580,000 | (6) | 01/07/2033 | Common Stock | 580,000 | (2) | 0 | D | ||||
| Employee Stock Option (right to buy) | $2.28 | 07/24/2023 | A | 580,000 | (6) | 01/07/2033 | Common Stock | 580,000 | (2) | 580,000 | D | ||||
| Explanation of Responses: |
| 1. Fully vested and exercisable. |
| 2. On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged. |
| 3. One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2020, subject to the Reporting Person continuing to provide service through each such date. |
| 4. One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 1, 2021, subject to the Reporting Person continuing to provide service through each such date. |
| 5. One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 5, 2022, subject to the Reporting Person continuing to provide service through each such date. |
| 6. One forty-eighth (1/48th) of the shares vested or shall vest on a monthly basis commencing on January 8, 2023, subject to the Reporting Person continuing to provide service through each such date. |
| Remarks: |
| /s/ Marc Belsky, Attorney-in-Fact | 07/26/2023 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
